Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines

Executive Summary

Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market

You may also be interested in...



Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs

Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.

2012 Wild Card: Will Guideline Revisions Drive Demand For Better Drugs?

NICE Guidance Expected To Add 1.4 Million To Roster Of Statin Users

An additional 1.4 million patients in England and Wales are expected to begin using statins as a result of guidance directing doctors to identify patients at high-risk for cardiovascular disease

Related Content

Topics

UsernamePublicRestriction

Register

PS044360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel